The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Cited by
Sorted by citations
Items 801–900 of 1,029
Evolution of ternary I–III–VI QDs: Synthesis, characterization and application
Tsolekile, N., Parani, S., Matoetoe, M. C., Songca, S. P., & Oluwafemi, O. S. (2017) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2017.08.012 · Cited by 102
Perfluorocarbon‐Based 19F MRI Nanoprobes for In Vivo Multicolor Imaging
Akazawa, K., Sugihara, F., Nakamura, T., Matsushita, H., Mukai, H., Akimoto, R., Minoshima, M., Mizukami, S., & Kikuchi, K. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201810363 · Cited by 102
Ding, Y., Wei, J., Li, S., Pan, Y., Wang, L., & Wang, R. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b09059 · Cited by 102
Radiolabeled PET/MRI Nanoparticles for Tumor Imaging
Forte, E., Fiorenza, D., Torino, E., di Polidoro, A. C., Cavaliere, C., Netti, P. A., Salvatore, M., & Aiello, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010089 · Cited by 105
Liu, S., Yang, J., Guo, R., Deng, L., Dong, A., & Zhang, J. (2020) · Macromolecular Rapid Communications · doi:10.1002/marc.201900570 · Cited by 102
Chen, Y., Zhang, X., Cheng, D., Zhang, Y., Liu, Y., Ji, L., Guo, R., Chen, H., Ren, X., Chen, Z., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00118 · Cited by 103
Khaledi, S., Jafari, S., Hamidi, S., Molavi, O., & Davaran, S. (2020) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2020.1743946 · Cited by 102
“Free drugs get absorbed by cancer cells mainly through diffusion [77].”
BackgroundWang, H., Ding, T., Guan, J., Liu, X., Wang, J., Jin, P., Hou, S., Lu, W., Qian, J., Wang, W., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c02821 · Cited by 102
Liu, Y., Zhou, J., Li, Q., Li, L., Jia, Y., Geng, F., Zhou, J., & Yin, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.019 · Cited by 103
Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems
Etter, E. L., Mei, K., & Nguyen, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113994 · Cited by 102
BH3-mimetics: recent developments in cancer therapy
Townsend, P. A., Kozhevnikova, M. V., Cexus, O., Zamyatnin, A. A., & Soond, S. M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02157-5 · Cited by 109
“While, CPPs can enhance cargo delivery of drugs using nanostructures [462, 471, 472], reduced specificity, resulting toxicity and reduced half-life can present challenges, as with most delivery systems of this nature [473, 474].”
BackgroundWang, Y., Xia, G., Tan, M., Wang, M., Li, Y., & Wang, H. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202113098 · Cited by 103
A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging
Zhang, H., Guo, Y., Jiao, J., Qiu, Y. N., Miao, Y., He, Y., Li, Z., Xia, C., Li, L., Cai, J., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00975-2 · Cited by 106
Exosome-like Nanovectors for Drug Delivery in Cancer
Arrighetti, N., Corbo, C., Evangelopoulos, M., Pastò, A., Zuco, V., & Tasciotti, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180831150259 · Cited by 102
Zhang, H., Cui, W., Qu, X., Wu, H., Qu, L., Zhang, X., Mäkilä, E. M., Salonen, J., Zhu, Y., Yang, Z., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817251116 · Cited by 101
“Some accumulation in the liver does occur because it is part of the clearance route from the body (36).”
A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery
Dogra, P., Butner, J. D., Ruiz-Ramírez, J., Chuang, Y.-L., Noureddine, A., Brinker, C. J., Vittorio Cristini, C., & Wang, Z. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.02.014 · Cited by 102
“Nonetheless, these interactions depend upon the physicochemical properties of the NPs [10,11], or the physiological state of the MPS [12], indicating that all NPs are not treated alike by the MPS, and manipulation of particle properties provides a way to regulate their sequestration by the MPS [13].”
BackgroundAbbina, S., Takeuchi, L. E., Anilkumar, P., Yu, K., Rogalski, J. C., Shenoi, R. A., Constantinescu, I., & Kizhakkedathu, J. N. (2020) · Nature Communications · doi:10.1038/s41467-020-16772-x · Cited by 107
Nanoscale drug delivery systems for controllable drug behaviors by multi-stage barrier penetration
Wang, J., Ni, Q., Wang, Y., Zhang, Y., He, H., Gao, D., Ma, X., & Liang, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.045 · Cited by 103
Transcytosis-enabled active extravasation of tumor nanomedicine
Zhou, Q., Li, J., Xiang, J., Shao, S., Zhou, Z., Tang, J., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114480 · Cited by 105
Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain
Wu, J. R., Hernández, Y. M., Miyasaki, K. F., & Kwon, E. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114820 · Cited by 108
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Wang, M., Yu, F., & Zhang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02214-5 · Cited by 110
Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology
Schwarz, B. H., Uchida, M., & Douglas, T. (2016) · Advances in virus research · doi:10.1016/bs.aivir.2016.09.002 · Cited by 100
“For biomedical applications, nanoparticles are small enough to travel through vasculature allowing them to circulate and interact at the tissue and cellular level within organisms (Blanco et al., 2015).”
BackgroundGanipineni, L. P., Učakar, B., Joudiou, N., Bianco, J. I., Danhier, P., Zhao, M., Bastiancich, C., Gallez, B., Danhier, F., & Véronique Préat, A. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165184 · Cited by 100
“10 nm) undergo opsonization and are cleared from systemic circulation via the reticuloendothelial system/ hepatobiliary pathway.(46) However, the rate of clearance is decreased by PEGylation due to steric resistance of opsonization and macrophage uptake processes, thereby greatly enhancing the resistance toward RES in…”
Ultrasound responsive mesoporous silica nanoparticles for biomedical applications
Manzano, M., & Vallet‐Regí, M. (2019) · Chemical Communications · doi:10.1039/c8cc09389j · Cited by 102
Jesus, S., Schmutz, M., Som, C., Borchard, G., Wick, P., & Borges, O. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00261 · Cited by 104
“TABLE 1 | Common routes of administration/exposure: important considerations relating nanomaterials characteristics and the various routes of exposure (Agrawal et al., 2014; Blanco et al., 2015; Date et al., 2016; Palmer and DeLouise, 2016; Boyes et al., 2017).”
BackgroundPolymeric Nanoparticles for the Treatment of Malignant Gliomas
Mahmoud, B. S., Alamri, A. H., & McConville, C. (2020) · Cancers · doi:10.3390/cancers12010175 · Cited by 104
Kamath, S. M., Rao, S. K., Jaison, D., Sridhar, K. R., Natarajan, K., Gopinath, V., Sivaperumal, P., & Shantanu Patil, S. (2020) · Process Biochemistry · doi:10.1016/j.procbio.2020.08.015 · Cited by 100
Recent Advances in Nanoparticle-Based Cancer Treatment: A Review
Bajpai, S., Tiwary, S. K., Sonker, M., Joshi, A., Gupta, V., Kumar, Y., Shreyash, N., & Biswas, S. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c00779 · Cited by 100
Kong, S. M., Costa, D. F. G., Jagielska, A., Vliet, K. J. V., & Hammond, P. T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104826118 · Cited by 100
Mahmoud, K. Y., Swidan, S. A., El-Nabarawi, M. A., & Teaima, M. H. M. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01309-9 · Cited by 106
Pharmacological Mechanisms and Clinical Applications of Curcumin: Update
Hao, M., Chu, Y., Lei, J., Yao, Z., Wang, P., Chen, Z., Wang, K., Sang, X., Han, X., Wang, L., et al. (2022) · Aging and Disease · doi:10.14336/ad.2022.1101 · Cited by 100
“According to the biological barriers in different diseases [198], kinds of nanomaterials were used to encapsulate curcumin forming nanoparticles, such as poly (lactic-co-glycolic acid) (PLGA) nanoparticles for cancer therapies [199], phenylboronic acid-conjugated chitosan nanoparticles [200], curcumin-loaded hybrid na…”
BackgroundWang, J., Zhao, W., Zhang, Z., Liu, X., Xie, T., Wang, L., Xue, Y., & Zhang, Y. (2024) · Advanced Materials · doi:10.1002/adma.202308915 · Cited by 104
Zhou, F., Feng, B., Wang, T., Wang, D., Meng, Q., Zeng, J., Zhang, Z., Wang, S., Yu, H., & Li, Y. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201606530 · Cited by 99
Choudhury, H., Gorain, B., Pandey, M., Khurana, R. K., & Kesharwani, P. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.042 · Cited by 102
In silico modelling of cancer nanomedicine, across scales and transport barriers
Stillman, N., Kovačević, M., Balaž, I., & Hauert, S. (2020) · npj Computational Materials · doi:10.1038/s41524-020-00366-8 · Cited by 99
Recent advances in targeted nanomedicine as promising antitumor therapeutics
Hejmady, S., Pradhan, R., Alexander, A., Agrawal, M., Singhvi, G., Gorain, B., Tiwari, S., Kesharwani, P., & Dubey, S. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.031 · Cited by 99
Strategies for Delivering Nanoparticles across Tumor Blood Vessels
Sheth, V. M., Wang, L., Bhattacharya, R., Mukherjee, P., & Wilhelm, S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202007363 · Cited by 106
Pan, T. S., Zhou, Q., Miao, K., Zhang, L., Wu, G., Yu, J., Xu, Y., Xiong, W., Li, Y., & Wang, Y. (2020) · Theranostics · doi:10.7150/thno.48152 · Cited by 101
“Over the past few decades, nanomedicines have emerged as potential platforms to overcome the pharmacokinetic obstacles associated with conventional medicines and have been shown to participate in the treatment of various diseases [15].”
BackgroundInfluentialIn Vivo T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design
Cevaal, P. M., Ali, A., Czuba‐Wojnilowicz, E., Symons, J., Lewin, S. R., Cortez‐Jugo, C., & Caruso, F. (2021) · ACS Nano · doi:10.1021/acsnano.0c09514 · Cited by 104
Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges
Bukhari, S. I., Imam, S. S., Ahmad, M. Z., Vuddanda, P. R., Alshehri, S., Mahdi, W. A., & Ahmad, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060840 · Cited by 100
“Lately, it has been verified that shape greatly impacts cellular uptake [106,107].”
BackgroundSubramaniam, S., Joyce, P., Thomas, N., & Prestidge, C. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113948 · Cited by 101
Current trends of targeted therapy for oral squamous cell carcinoma
Li, H., Zhang, Y., Xu, M., & Yang, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04028-8 · Cited by 102
Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy
Jin, Z., Gao, Q., Wu, K., Ouyang, J., Guo, W., & Liang, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115111 · Cited by 110
Targeted Delivery of Immunomodulators to Lymph Nodes
Azzi, J. R., Yin, Q., Uehara, M., Ohori, S., Tang, L., Cai, K., Ichimura, T., McGrath, M. M., Maarouf, O. H., Kefaloyianni, E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.007 · Cited by 101
“Reducing the size of particles (~100 nm) would allow them to evade lung entrapment and avoid rapid clearance by the MPS, leading to a longer circulation time and therefore increased delivery to LNs (Blanco et al., 2015).”
Feng, Q., Shen, Y., Fu, Y., Muroski, M. E., Zhang, P., Wang, Q., Xu, C., Lesniak, M. S., Li, G., & Cheng, Y. (2017) · Theranostics · doi:10.7150/thno.18985 · Cited by 99
“Achieving this goal is vitally important because these barriers are interconnected, and simply overcoming one individual barrier is not adequate to produce proper therapeutic outcomes [51, 52].”
BackgroundNexus between in silico and in vivo models to enhance clinical translation of nanomedicine
Moradi Kashkooli, F., Soltani, M., Souri, M., Meaney, C., & Kohandel, M. (2021) · Nano Today · doi:10.1016/j.nantod.2020.101057 · Cited by 120
Exosome-Based Delivery of Natural Products in Cancer Therapy
Song, H., Liu, B., Dong, B., Xu, J., Zhou, H., Na, S., Liu, Y., Pan, Y., Chen, F., Li, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650426 · Cited by 101
Chen, L., Huang, Q., Zhao, T., Sui, L., Wang, S., Xiao, Z., Nan, Y., & Ai, K. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102046 · Cited by 99
“6B) [120 – 123].”
Current progress and prospects of organic nanoparticles against bacterial biofilm
Li, X., Chen, D., & Xie, S. (2021) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2021.102475 · Cited by 101
Caro, C., Avasthi, A., Páez-Muñoz, J. M., Leal, M. P., & García‐Martín, M. L. (2021) · Biomaterials Science · doi:10.1039/d1bm01398j · Cited by 101
Zhu, L., Luo, M., Zhang, Y., Fang, F., Li, M., An, F., Zhao, D., & Zhang, J. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214875 · Cited by 100
‘Passive’ nanoparticles for organ-selective systemic delivery: design, mechanism and perspective
Fu, L., Zhang, Y., Farokhzad, R. A., Mendes, B. B., Conde, J., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00998f · Cited by 100
Three ‘E’ challenges for siRNA drug development
Guo, S., Zhang, M., & Huang, Y. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.10.005 · Cited by 104
Tuning the Drug Loading and Release of DNA‐Assembled Gold‐Nanorod Superstructures
Raeesi, V., Chou, L. Y. T., & Chan, W. C. W. (2016) · Advanced Materials · doi:10.1002/adma.201600773 · Cited by 97
Hydroxyethyl starch stabilized polydopamine nanoparticles for cancer chemotherapy
Wu, H., Hu, H., Wan, J., Li, Y., Wu, Y., Tang, Y., Xiao, C., Xu, H., Yang, X., & Li, Z. (2018) · Chemical Engineering Journal · doi:10.1016/j.cej.2018.05.082 · Cited by 98
Polymeric micro- and nanoparticles for immune modulation
Ben‐Akiva, E., Est-Witte, S. E., Meyer, R. A., Rhodes, K. R., & Green, J. J. (2018) · Biomaterials Science · doi:10.1039/c8bm01285g · Cited by 97
Polymeric siRNA gene delivery – transfection efficiency versus cytotoxicity
Kargaard, A., Sluijter, J. P. G., & Klumperman, B. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.046 · Cited by 100
Peng, C., Huang, Y., & Zheng, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.020 · Cited by 98
Oral delivery of sorafenib through spontaneous formation of ionic liquid nanocomplexes
Shi, Y., Zhao, Z., Gao, Y., Pan, D. C., Salinas, A. K., Tanner, E. E. L., Guo, J., & Mitragotri, S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.018 · Cited by 98
Dual Size/Charge‐Switchable Nanocatalytic Medicine for Deep Tumor Therapy
Wu, W., Pu, Y., & Shi, J. (2021) · Advanced Science · doi:10.1002/advs.202002816 · Cited by 97
Nanoparticle entry into cells; the cell biology weak link
Griffiths, G. W., Grüenberg, J., Marsh, M., Wohlmann, J., Jones, A. T., & Parton, R. G. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114403 · Cited by 101
Zou, D., Wu, Z., Yi, X., Hui, Y., Yang, G., Liu, Y., Tengjisi, Wang, H., Brooks, A., Wang, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214757120 · Cited by 99
“Nanoparticles (NPs) have been explored as a promising platform for drug delivery and tumor targeting (1–3).”
Targeted therapy of kidney disease with nanoparticle drug delivery materials
Shang, S., Li, X., Wang, H., Zhou, Y., Pang, K., Li, P., Liu, X., Zhang, M., Li, W., Li, Q., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.03.014 · Cited by 105
“Third, particle shape [43].”
Drug loading and delivery using nanofibers scaffolds
Mohammadian, F., & Eatemadi, A. (2016) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2016.1185726 · Cited by 97
“Due to simplify in their design, these nanofibers were viewed as vectors for drug delivery that improved pharmacokinetic parameters, such as blood-residence times, providing an effective means to an end (Blanco et al. 2015).”
BackgroundInfluentialCai, K., Zhang, W., Zhang, J., Li, H., Han, H., & Zhai, T. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b12758 · Cited by 96
Wang, G., Li, Q., Chen, D., Wu, B., Wu, Y., Tong, W., & Huang, P. (2019) · Theranostics · doi:10.7150/thno.37538 · Cited by 96
“Considering that endosomes/ lysosomes have lower pH and different hydrolytic enzymes can devitalize and decompose exogenous substances including drug loaded-nanoparticles and consequently weaken or even inactivate the drug effect [40, 41], rapid and efficient endo-lysosomal escape is one of important characters of the…”
BackgroundCargo transport through the nuclear pore complex at a glance
Paci, G., Caria, J., & Lemke, E. A. (2021) · Journal of Cell Science · doi:10.1242/jcs.247874 · Cited by 96
“These systems comprise different types of nanoparticles that are easily synthetized and can be surface modified (Blanco et al., 2015; Fortuni et al., 2019).”
BackgroundOverview of Physicochemical Properties of Nanoparticles as Drug Carriers for Targeted Cancer Therapy
Yagublu, V., Karimova, A., Hajibabazade, J., Reißfelder, C., Muradov, M., Stefano Bellucci, A., & Allahverdiyev, A. (2022) · Journal of Functional Biomaterials · doi:10.3390/jfb13040196 · Cited by 100
“These include the reticuloendothelial system (RES), comprised of the liver, spleen, lungs, and bone marrow [17,18]; the endothelium of blood vessels within the target tissues [19]; and the extracellular matrix (ECM) of the target tissue [20,21], which is a highly organized and complex network of structural proteins, p…”
BackgroundMicro/Nanorobotic Swarms: From Fundamentals to Functionalities
Law, J., Yu, J., Tang, W., Gong, Z., Wang, X., & Sun, Y. (2023) · ACS Nano · doi:10.1021/acsnano.2c11733 · Cited by 97
Long, X., Liu, M., Nan, Y., Chen, Q., Xiao, Z., Xiang, Y., Ying, X., Sun, J., Huang, Q., & Ai, K. (2024) · Advanced Materials · doi:10.1002/adma.202308239 · Cited by 97
Barz, M., Parak, W. J., & Zentel, R. (2024) · Advanced Science · doi:10.1002/advs.202402935 · Cited by 104
Shen, S., Zhang, Y., Chen, K., Luo, Y., & Wang, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00997 · Cited by 95
Li, J., Meng, X., Deng, J., Lu, D., Zhang, X., Chen, Y., Zhu, J., Fan, A., Ding, D., Kong, D., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b06299 · Cited by 95
mRNA Delivery System for Targeting Antigen‐Presenting Cells In Vivo
Fornaguera, C., Guerra‐Rebollo, M., Lázaro, M. Á., Castells‐Sala, C., Meca‐Cortés, Ó., Ramos‐Pérez, V., Cascante, A., Rubio, N., Blanco, J., & Borrós, S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800335 · Cited by 94
Doped Graphene Quantum Dots for Intracellular Multicolor Imaging and Cancer Detection
Campbell, E., Hasan, M. T., González-Rodríguez, R., Akkaraju, G. R., & Naumov, A. V. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00603 · Cited by 95
An, Y., Zhu, J., Liu, F., Deng, J., Meng, X., Liu, G., Wu, H., Fan, A., Wang, Z., & Zhao, Y. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b10954 · Cited by 95
Tang, H., Li, Q., Yan, W., & Jiang, X. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101609 · Cited by 95
Wen, P., Huang, H., Zhang, R., Zheng, H., Liang, T., Zhuang, C., Wu, Q., Wang, J., Liu, F., Zhang, K., et al. (2025) · Nature Chemistry · doi:10.1038/s41557-024-01705-8 · Cited by 101
Wu, S., Zhang, A., Li, S., Chatterjee, S., Qi, R., Segura-Ibarra, V., Mauro Ferrari, B., Gupte, A. A., Blanco, E., & Hamilton, D. J. (2018) · Advanced Science · doi:10.1002/advs.201700530 · Cited by 96
Self-citationYu, B., Goel, S., Ni, D., Ellison, P. A., Siamof, C. M., Jiang, D., Cheng, L., Kang, L., Yu, F., Liu, Z., et al. (2018) · Advanced Materials · doi:10.1002/adma.201704934 · Cited by 94
A review on core–shell structured unimolecular nanoparticles for biomedical applications
Chen, G., Wang, Y., Xie, R., & Gong, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.008 · Cited by 95
Li, Y., Bolinger, J., Yu, Y., Glass, Z., Shi, N., Yang, L., Wang, M., & Xu, Q. (2018) · Biomaterials Science · doi:10.1039/c8bm00637g · Cited by 96
Wang, Y., Yang, M., Qian, J., Xu, W., Wang, J., Hou, G., Ji, L., & Suo, A. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.09.035 · Cited by 94
Abumanhal-Masarweh, H., Koren, L., Zinger, A., Yaari, Z. A., Krinsky, N., Kaneti, G., Dahan, N., Lupu-Haber, Y., Suss-Toby, E., Weiss‐Messer, E., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.004 · Cited by 94
Zhu, J., Sevencan, C., Zhang, M., McCoy, R. S. A., Ding, X., Ye, J., Xie, J., Ariga, K., Feng, J. X., Bay, B., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b08798 · Cited by 95
Agar/κ-carrageenan/montmorillonite nanocomposite hydrogels for wound dressing applications
Polat, T. G., Duman, O., & Tunç, S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.09.048 · Cited by 94
Xue, C., Sutrisno, L., Li, M., Zhu, W. Z., Yang, F., Liu, C., Wang, X., Cai, K., Hu, Y., & Luo, Z. Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120623 · Cited by 94
Biomimetic Targeted Theranostic Nanoparticles for Breast Cancer Treatment
Marshall, S. K., Angsantikul, P., Pang, Z., Nasongkla, N., Hussen, R. S. D., & Thamphiwatana, S. (2022) · Molecules · doi:10.3390/molecules27196473 · Cited by 94
Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery
Li, W., Yalçın, M., Lin, Q., Ardawi, M. M., & Mousa, S. A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.009 · Cited by 95
Reifarth, M., Hoeppener, S., & Schubert, U. S. (2018) · Advanced Materials · doi:10.1002/adma.201703704 · Cited by 94
Feng, S., Hu, Y., Peng, S., Han, S., Tao, H., Zhang, Q., Xu, X., Zhang, J., & Hu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.003 · Cited by 92
The Promise and Challenge of In Vivo Delivery for Genome Therapeutics
Wilson, R. C., & Gilbert, L. A. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00680 · Cited by 98
Costa, S. A., Mozhdehi, D., Dzuricky, M. J., Isaacs, F. J., Brustad, E. M., & Chilkoti, A. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b03837 · Cited by 96
Implications of nanotechnology for the treatment of cancer: Recent advances
Klochkov, S. G., Неганова, М. Е., Nikolenko, V. N., Chen, K., Somasundaram, S. G., Kirkland, C. E., & Aliev, G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.028 · Cited by 97
Smart magnetic resonance imaging-based theranostics for cancer
Brito, B., Price, T. W., Gallo, J., Bañobre‐López, M., & Stasiuk, G. J. (2021) · Theranostics · doi:10.7150/thno.57004 · Cited by 97
“These nanoparticles had large average sizes (219 ± 52 nm), which might contribute to a longer blood circulation half-life but could hinder their ability to extravasate to tumour tissues [174, 175].”
BackgroundShen, X., Pan, D., Gong, Q., Gu, Z., & Luo, K. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.017 · Cited by 96
“Drug penetration becomes more critical for larger tumors [97,98].”
BackgroundKim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Preparation of Targeted Lignin–Based Hollow Nanoparticles for the Delivery of Doxorubicin
Zhou, Y., Han, Y., Li, G., Yang, S., Xiong, F., & Chu, F. (2019) · Nanomaterials · doi:10.3390/nano9020188 · Cited by 92
“Small molecule drugs can simply diffuse and distribute freely throughout the body [3], thereby resulting in undesirable side effects that can limit the achievement of proper doses in humans [4].”
Nanoparticle opsonization: forces involved and protection by long chain polymers
Wani, T. U., Raza, S. N., & Khan, N. A. (2019) · Polymer Bulletin · doi:10.1007/s00289-019-02924-7 · Cited by 96
Hayashi, Y., Takamiya, M., Jensen, P. B., Ojea‐Jiménez, I., Claude, H., Antony, C., Kjær-Sørensen, K., Grabher, C., Boesen, T. P., Gilliland, D. D., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b07233 · Cited by 90
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
